Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells (TCA Cellular Therapy)
- Development stage
- Unknown
- Lead developer
- TCA Cellular Therapy
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
Autologous bone marrow-derived mesenchymal stem cells (MSCs) developed by TCA Cellular Therapy are an experimental cell therapy for the treatment of spinal cord injury (SCI). The therapeutic process involves harvesting a patient's own bone marrow, followed by the ex-vivo expansion of the mesenchymal stem cell population. These expanded cells are then administered back to the patient via a single intrathecal infusion. The mechanism of action is primarily paracrine; the MSCs are thought to migrate to the site of injury and secrete a variety of neurotrophic factors and anti-inflammatory cytokines. This activity aims to modulate the local immune response, reduce secondary injury, provide neuroprotection, and potentially support the regeneration of damaged neural tissue to improve neuromuscular control and sensory function.
- Other names
- autologous bone marrow-derived mesenchymal stem cellsautologous MSCsBM-MSCsbone marrow-derived mesenchymal stem cells
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells (TCA Cellular Therapy).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (TCA Cellular Therapy).